Daniel Diolaiti
Overview
Explore the profile of Daniel Diolaiti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mundi P, Dela Cruz F, Grunn A, Diolaiti D, Mauguen A, Rainey A, et al.
Cancer Discov
. 2023 Apr;
13(6):1386-1407.
PMID: 37061969
Significance: Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology...
2.
Coutinho D, Mundi P, Marks L, Burke C, Ortiz M, Diolaiti D, et al.
Med
. 2022 Oct;
3(11):774-791.e7.
PMID: 36195086
Background: Malignant rhabdoid tumors (MRTs) and Wilms' tumors (WTs) are rare and aggressive renal tumors of infants and young children comprising ∼5% of all pediatric cancers. MRTs are among the...
3.
Purohit V, Wang L, Yang H, Li J, Ney G, Gumkowski E, et al.
Genes Dev
. 2021 Jan;
35(3-4):218-233.
PMID: 33446568
Pancreatic ductal adenocarcinoma is a lethal disease characterized by late diagnosis, propensity for early metastasis and resistance to chemotherapy. Little is known about the mechanisms that drive innate therapeutic resistance...
4.
Hoshino A, Kim H, Bojmar L, Gyan K, Cioffi M, Hernandez J, et al.
Cell
. 2020 Aug;
182(4):1044-1061.e18.
PMID: 32795414
There is an unmet clinical need for improved tissue and liquid biopsy tools for cancer detection. We investigated the proteomic profile of extracellular vesicles and particles (EVPs) in 426 human...
5.
Wang L, Yang H, Zamperone A, Diolaiti D, Palmbos P, Abel E, et al.
Genes Dev
. 2019 May;
33(11-12):641-655.
PMID: 31048544
Pancreatic adenocarcinoma (PDA) is an aggressive disease driven by oncogenic KRAS and characterized by late diagnosis and therapeutic resistance. Here we show that deletion of the ataxia-telangiectasia group D-complementing ()...
6.
Slotkin E, Diolaiti D, Shukla N, Dela Cruz F, Clark J, Gundem G, et al.
Cancer Discov
. 2019 Mar;
9(5):605-616.
PMID: 30877085
Despite the important role of the PI3K/AKT/mTOR axis in the pathogenesis of cancer, to date there have been few functional oncogenic fusions identified involving the genes. A 12-year-old female with...
7.
Diolaiti D, Dela Cruz F, Gundem G, Bouvier N, Boulad M, Zhang Y, et al.
Cold Spring Harb Mol Case Stud
. 2018 Dec;
4(6).
PMID: 30552129
-rearranged tumors are defined by the presence of a gene fusion between and various gene partners and typically follow a clinically aggressive disease course with poor outcomes despite conventional multimodality...
8.
Alvarez M, Subramaniam P, Tang L, Grunn A, Aburi M, Rieckhof G, et al.
Nat Genet
. 2018 Jun;
50(7):979-989.
PMID: 29915428
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their...
9.
Efimenko E, Dave U, Lebedeva I, Shen Y, Sanchez-Quintero M, Diolaiti D, et al.
Mol Cancer Ther
. 2017 Jul;
16(10):2069-2082.
PMID: 28716817
PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110γ and...
10.
Hsiao S, Karajannis M, Diolaiti D, Mansukhani M, Glade Bender J, Kung A, et al.
Cold Spring Harb Mol Case Stud
. 2017 Mar;
3(2):a001396.
PMID: 28299358
Pleomorphic xanthoastrocytoma (PXA) is a World Health Organization (WHO) Grade II glioma occurring primarily in children and young adults. Most PXAs harbor the known activating mutation V600E. We report a...